Susquehanna International Group, LLP Compass Pathways PLC Call Options Transaction History

Susquehanna International Group, LLP

16 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	N/A	141,400 Added 412.24%	175,700 $1.5 Million
Q2 2024 Aug 15, 2024	SELL	N/A	-15,800 Reduced 31.54%	34,300 $292,000
Q1 2024 May 07, 2024	BUY	N/A	21,900 Added 77.66%	50,100 $427,000
Q4 2023 Feb 14, 2024	BUY	N/A	17,100 Added 154.05%	28,200 $240,000
Q3 2023 Nov 14, 2023	SELL	N/A	-11,600 Reduced 51.1%	11,100 $94,000
Q2 2023 Aug 11, 2023	SELL	$7.79 - $10.69 $179,949 - $246,939	-23,100 Reduced 50.44%	22,700 $193,000
Q1 2023 May 16, 2023	BUY	$7.32 - $10.85 $137,616 - $203,980	18,800 Added 69.63%	45,800 $454,000
Q4 2022 Feb 14, 2023	SELL	$7.84 - $11.68 $242,256 - $360,912	-30,900 Reduced 53.37%	27,000 $216,000
Q3 2022 Nov 14, 2022	BUY	$10.73 - $20.07 $167,388 - $313,092	15,600 Added 36.88%	57,900 $621,000
Q2 2022 Aug 15, 2022	SELL	$6.76 - $14.18 $152,100 - $319,050	-22,500 Reduced 34.72%	42,300 $458,000
Q1 2022 May 16, 2022	SELL	$11.13 - $23.04 $1.71 Million - $3.54 Million	-153,800 Reduced 70.36%	64,800 $835,000
Q4 2021 Feb 14, 2022	SELL	$21.81 - $48.96 $2.2 Million - $4.94 Million	-100,900 Reduced 31.58%	218,600 $4.83 Million
Q3 2021 Nov 15, 2021	BUY	$29.03 - $38.62 $6.08 Million - $8.09 Million	209,500 Added 190.45%	319,500 $9.54 Million
Q2 2021 Aug 11, 2021	SELL	$32.29 - $39.68 $3.48 Million - $4.28 Million	-107,900 Reduced 49.52%	110,000 $4.2 Million
Q1 2021 May 17, 2021	BUY	$34.75 - $57.5 $3.19 Million - $5.27 Million	91,700 Added 72.66%	217,900 $8.02 Million
Q4 2020 Feb 16, 2021	BUY	$32.0 - $59.2 $4.04 Million - $7.47 Million	126,200 New	126,200 $6.01 Million

151

33.6M

536K

582K

Ticker CMPS
Exchange NASDAQ
Sector Healthcare
Industry Medical Care Facilities
Shares Outstandng 42,522,400
Market Cap $363M
Description
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. Th...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.